Lijun Rong

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9066438/publications.pdf

Version: 2024-02-01

68	2,327	236925	243625
papers	citations	25 h-index	44 g-index

72	72	72	2750
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	LAYN Is a Prognostic Biomarker and Correlated With Immune Infiltrates in Gastric and Colon Cancers. Frontiers in Immunology, 2019, 10, 6.	4.8	280
2	Comprehensive Analysis of Ebola Virus GP1 in Viral Entry. Journal of Virology, 2005, 79, 4793-4805.	3.4	144
3	Design of SARS-CoV-2 PLpro Inhibitors for COVID-19 Antiviral Therapy Leveraging Binding Cooperativity. Journal of Medicinal Chemistry, 2022, 65, 2940-2955.	6.4	102
4	Lignans and Their Derivatives from Plants as Antivirals. Molecules, 2020, 25, 183.	3.8	92
5	Inhibition of Ebola and Marburg Virus Entry by G Protein-Coupled Receptor Antagonists. Journal of Virology, 2015, 89, 9932-9938.	3.4	90
6	Direct detection of human adenovirus or SARS-CoV-2 with ability to inform infectivity using DNA aptamer-nanopore sensors. Science Advances, 2021, 7, eabh2848.	10.3	87
7	RNAâ€dependent RNA polymerase of SARSâ€CoVâ€2 as a therapeutic target. Journal of Medical Virology, 2021, 93, 300-310.	5.0	82
8	New Small Molecule Entry Inhibitors Targeting Hemagglutinin-Mediated Influenza A Virus Fusion. Journal of Virology, 2014, 88, 1447-1460.	3.4	72
9	Potent Inhibitor of Drug-Resistant HIV-1 Strains Identified from the Medicinal Plant Justicia gendarussa. Journal of Natural Products, 2017, 80, 1798-1807.	3.0	71
10	Engineered ACE2 decoy mitigates lung injury and death induced by SARS-CoV-2 variants. Nature Chemical Biology, 2022, 18, 342-351.	8.0	63
11	Influenza Virus: Small Molecule Therapeutics and Mechanisms of Antiviral Resistance. Current Medicinal Chemistry, 2019, 25, 5115-5127.	2.4	60
12	Role of EXT1 and Glycosaminoglycans in the Early Stage of Filovirus Entry. Journal of Virology, 2015, 89, 5441-5449.	3.4	54
13	Competitive Cooperation of Hemagglutinin and Neuraminidase during Influenza A Virus Entry. Viruses, 2019, 11, 458.	3.3	52
14	Anti-HIV diphyllin glycosides from Justicia gendarussa. Phytochemistry, 2017, 136, 94-100.	2.9	51
15	Novel Small Molecule Entry Inhibitors of Ebola Virus. Journal of Infectious Diseases, 2015, 212, S425-S434.	4.0	49
16	Ginkgolic acid and anacardic acid are specific covalent inhibitors of SARS-CoV-2 cysteine proteases. Cell and Bioscience, 2021, 11, 45.	4.8	47
17	Identification of Ellagic Acid from Plant Rhodiola rosea L. as an Anti-Ebola Virus Entry Inhibitor. Viruses, 2018, 10, 152.	3.3	45
18	Discovery of chebulagic acid and punicalagin as novel allosteric inhibitors of SARS-CoV-2 3CLpro. Antiviral Research, 2021, 190, 105075.	4.1	44

#	Article	IF	Citations
19	Targeting SARSâ€CoVâ€2 viral proteases as a therapeutic strategy to treat COVIDâ€19. Journal of Medical Virology, 2021, 93, 2722-2734.	5.0	41
20	A Comparative High-Throughput Screening Protocol to Identify Entry Inhibitors of Enveloped Viruses. Journal of Biomolecular Screening, 2014, 19, 100-107.	2.6	37
21	Inter-domain communication in SARS-CoV-2 spike proteins controls protease-triggered cell entry. Cell Reports, 2022, 39, 110786.	6.4	37
22	Identification of Chebulinic Acid and Chebulagic Acid as Novel Influenza Viral Neuraminidase Inhibitors. Frontiers in Microbiology, 2020, 11, 182.	3.5	36
23	Glycosylated diphyllin as a broad-spectrum antiviral agent against Zika virus. EBioMedicine, 2019, 47, 269-283.	6.1	34
24	Identification of a New Region of SARS-CoV S Protein Critical for Viral Entry. Journal of Molecular Biology, 2009, 394, 600-605.	4.2	31
25	ACE2-IgG1 fusions with improved inÂvitro and inÂvivo activity against SARS-CoV-2. IScience, 2022, 25, 103670.	4.1	29
26	Identification of a coumarin-based antihistamine-like small molecule as an anti-filoviral entry inhibitor. Antiviral Research, 2017, 145, 24-32.	4.1	26
27	Label-Free Digital Detection of Intact Virions by Enhanced Scattering Microscopy. Journal of the American Chemical Society, 2022, 144, 1498-1502.	13.7	26
28	Inhibition of Influenza H7 Hemagglutinin-Mediated Entry. PLoS ONE, 2013, 8, e76363.	2.5	25
29	Identification of Diaryl-Quinoline Compounds as Entry Inhibitors of Ebola Virus. Viruses, 2018, 10, 678.	3.3	24
30	Repurposing potential of 1st generation H1-specific antihistamines as anti-filovirus therapeutics. Antiviral Research, 2018, 157, 47-56.	4.1	24
31	Punicalagin is a neuraminidase inhibitor of influenza viruses. Journal of Medical Virology, 2021, 93, 3465-3472.	5.0	23
32	Small Molecule Inhibitors of Influenza Virus Entry. Pharmaceuticals, 2021, 14, 587.	3.8	23
33	Optimization of 4-Aminopiperidines as Inhibitors of Influenza A Viral Entry That Are Synergistic with Oseltamivir. Journal of Medicinal Chemistry, 2020, 63, 3120-3130.	6.4	21
34	SARS-CoV-2 cell entry and targeted antiviral development. Acta Pharmaceutica Sinica B, 2021, 11, 3879-3888.	12.0	21
35	Characterization of the receptor-binding domain of Ebola glycoprotein in viral entry. Virologica Sinica, 2011, 26, 156-70.	3.0	19
36	Application of virus-like particles (VLP) to NMR characterization of viral membrane protein interactions. Journal of Biomolecular NMR, 2016, 64, 255-265.	2.8	18

#	Article	IF	Citations
37	Identification of critical residues of influenza neuraminidase in viral particle release. Virology Journal, 2011, 8, 14.	3.4	17
38	Cell-Based High-Throughput Screening Assay Identifies 2â€²,2â€²-Difluoro-2â€²-deoxycytidine Gemcitabine as a Potential Antipoliovirus Agent. ACS Infectious Diseases, 2017, 3, 45-53.	3.8	17
39	Discovery and Structural Optimization of 4-(Aminomethyl)benzamides as Potent Entry Inhibitors of Ebola and Marburg Virus Infections. Journal of Medicinal Chemistry, 2020, 63, 7211-7225.	6.4	16
40	Evidence for distinct mechanisms of small molecule inhibitors of filovirus entry. PLoS Pathogens, 2021, 17, e1009312.	4.7	16
41	Molecular Mechanism Underlying the Action of Influenza A Virus Fusion Inhibitor MBX2546. ACS Infectious Diseases, 2017, 3, 330-335.	3.8	15
42	A Simple and Robust Approach for Evaluation of Antivirals Using a Recombinant Influenza Virus Expressing Gaussia Luciferase. Viruses, 2018, 10, 325.	3.3	15
43	A Parallel Phenotypic Versus Target-Based Screening Strategy for RNA-Dependent RNA Polymerase Inhibitors of the Influenza A Virus. Viruses, 2019, 11, 826.	3.3	15
44	Current Development of Glioblastoma Therapeutic Agents. Molecular Cancer Therapeutics, 2021, 20, 1521-1532.	4.1	15
45	A Mechanism Underlying Attenuation of Recombinant Influenza A Viruses Carrying Reporter Genes. Viruses, 2018, 10, 679.	3.3	14
46	Flu Universal Vaccines: New Tricks on an Old Virus. Virologica Sinica, 2021, 36, 13-24.	3.0	14
47	Signal-regulatory protein alpha is an anti-viral entry factor targeting viruses using endocytic pathways. PLoS Pathogens, 2021, 17, e1009662.	4.7	14
48	Identification of entry inhibitors with 4-aminopiperidine scaffold targeting group 1 influenza A virus. Antiviral Research, 2020, 177, 104782.	4.1	13
49	Structure of avian influenza hemagglutinin in complex with a small molecule entry inhibitor. Life Science Alliance, 2020, 3, e202000724.	2.8	13
50	A parallel genome-wide RNAi screening strategy to identify host proteins important for entry of Marburg virus and H5N1 influenza virus. Virology Journal, 2015, 12, 194.	3.4	12
51	Identification of a novel inhibitor targeting influenza A virus group 2 hemagglutinins. Antiviral Research, 2021, 186, 105013.	4.1	12
52	Stable Axially Chiral Isomers of Arylnaphthalene Lignan Glycosides with Antiviral Potential Discovered from Justicia procumbens. Journal of Organic Chemistry, 2021, 86, 5568-5583.	3.2	12
53	Screening and Reverse-Engineering of Estrogen Receptor Ligands as Potent Pan-Filovirus Inhibitors. Journal of Medicinal Chemistry, 2020, 63, 11085-11099.	6.4	11
54	Mutagenesis Studies of the H5 Influenza Hemagglutinin Stem Loop Region. Journal of Biological Chemistry, 2014, 289, 22237-22245.	3.4	10

#	Article	IF	Citations
55	Development of coumarine derivatives as potent anti-filovirus entry inhibitors targeting viral glycoprotein. European Journal of Medicinal Chemistry, 2020, 204, 112595.	5.5	10
56	Development of Potential Small Molecule Therapeutics for Treatment of Ebola Virus Disease. Current Medicinal Chemistry, 2019, 25, 5177-5190.	2.4	9
57	Stabilization and Improvement of a Promising Influenza Antiviral: Making a PAIN PAINless. ACS Infectious Diseases, 2016, 2, 608-615.	3.8	8
58	Bis-biguanide dihydrochloride inhibits intracellular replication of M. tuberculosis and controls infection in mice. Scientific Reports, 2016, 6, 32725.	3.3	8
59	Generation of a Reassortant Influenza A Subtype H3N2 Virus Expressing Gaussia Luciferase. Viruses, 2019, 11, 665.	3.3	8
60	Screening for Anti-Influenza Actives of Prefractionated Traditional Chinese Medicines. Evidence-based Complementary and Alternative Medicine, 2020, 2020, 1-7.	1.2	8
61	A recombinant Cedar virus based high-throughput screening assay for henipavirus antiviral discovery. Antiviral Research, 2021, 193, 105084.	4.1	5
62	A Mother-to-Child Transmission Study in Nigeria: The Impact of Maternal HIV Infection and HAART on Plasma Immunoglobulins, Cytokine Profiles and Infant Outcome. Virologica Sinica, 2020, 35, 468-477.	3.0	4
63	Biological differentiation of traditional Chinese medicine from excessive to deficient syndromes in AIDS: Comparative microRNA microarray profiling and syndromeâ€specific biomarker identification. Journal of Medical Virology, 2021, 93, 3634-3646.	5.0	4
64	Identification of the SARS-CoV-2 Entry Receptor ACE2 as a Direct Target for Transcriptional Repression by Miz1. Frontiers in Immunology, 2021, 12, 648815.	4.8	4
65	Ebola Virus Entry Inhibitors. Advances in Experimental Medicine and Biology, 2022, 1366, 155-170.	1.6	3
66	Ebola Entry Inhibitors Discovered from Maesa perlarius. International Journal of Molecular Sciences, 2022, 23, 2620.	4.1	2
67	Comparative analyses of small molecule and antibody inhibition on glycoproteinâ€mediated entry of MÄ›nglÃ virus with other filoviruses. Journal of Medical Virology, 2022, , .	5.0	2
68	3,4-Seco-Isopimarane Diterpenes from the Twigs and Leaves of Isodon Flavidus. Molecules, 2022, 27, 3098.	3.8	2